Cytomyx Therapeutics
CytomX Therapeutics is a clinical-stage biopharmaceutical company focused on oncology, dedicated to revolutionizing cancer treatment through innovative approaches. Utilizing its Probody® platform technology, it aims to develop highly potent and specific biologics activated exclusively within tumor cells, minimizing toxic side effects on healthy tissues. The company has an extensive pipeline of candidate products in various stages of clinical development targeting solid and liquid tumors, including lung, breast, pancreatic, and blood cancers.
Industries
Nr. of Employees
medium (51-250)
Products
Antibody–drug conjugate targeting NTSR1 for pancreatic cancer (Phase 1/2)
A receptor-targeted antibody–drug conjugate designed to deliver cytotoxic payloads to cells expressing neurotensin receptor 1 for treatment of pancreatic cancer; reported as in Phase 1/2 clinical development.
Antibody–drug conjugate targeting SSTR2 for pancreatic, gastric, and colon cancers (Phase 1/2)
A receptor-targeted antibody–drug conjugate directed at somatostatin receptor 2 for treatment of pancreatic, gastric, and colorectal malignancies; reported as in Phase 1/2 clinical development.
Antibody–drug conjugate targeting PTH1R for thyroid cancer (Phase 1/2)
A receptor-targeted antibody–drug conjugate designed to target parathyroid hormone 1 receptor for treatment of thyroid cancer; reported as in Phase 1/2 clinical development.
Antibody–drug conjugate targeting NTSR1 for pancreatic cancer (Phase 1/2)
A receptor-targeted antibody–drug conjugate designed to deliver cytotoxic payloads to cells expressing neurotensin receptor 1 for treatment of pancreatic cancer; reported as in Phase 1/2 clinical development.
Antibody–drug conjugate targeting SSTR2 for pancreatic, gastric, and colon cancers (Phase 1/2)
A receptor-targeted antibody–drug conjugate directed at somatostatin receptor 2 for treatment of pancreatic, gastric, and colorectal malignancies; reported as in Phase 1/2 clinical development.
Antibody–drug conjugate targeting PTH1R for thyroid cancer (Phase 1/2)
A receptor-targeted antibody–drug conjugate designed to target parathyroid hormone 1 receptor for treatment of thyroid cancer; reported as in Phase 1/2 clinical development.
Services
Collaborative development of receptor-targeted and conditionally activated biologics through discovery, preclinical evaluation, and Phase 1/2 clinical studies; potential for partnership or licensing.
Collaborative development of receptor-targeted and conditionally activated biologics through discovery, preclinical evaluation, and Phase 1/2 clinical studies; potential for partnership or licensing.
Expertise Areas
- Oncology drug development
- Conditionally activated biologics
- Antibody–drug conjugate development
- Receptor-targeted therapeutics
Key Technologies
- Conditionally activated biologics platform
- Antibody–drug conjugates (ADCs)
- Receptor-directed targeting
- Early-phase clinical development protocols
News & Updates
Unlocking new possibilities in cancer treatment, CytomX's diverse pipeline of candidate products is paving the way for improved therapies in solid and liquid tumor types.
Exciting strides in cancer therapy! CytomX Therapeutics is redefining the future of cancer treatment through groundbreaking innovations.
Glycan-based therapeutics are gaining traction as a revolutionary approach in medicine, with glycoscience emerging as a pivotal field.
Guanabenz, an antihypertensive agent, has forensic applications in drug toxicity, criminal investigations, and veterinary medicine. The Guanabenz Forensic Kit aids in its detection.
Unlocking new possibilities in cancer treatment, CytomX's diverse pipeline of candidate products is paving the way for improved therapies in solid and liquid tumor types.
Exciting strides in cancer therapy! CytomX Therapeutics is redefining the future of cancer treatment through groundbreaking innovations.
Glycan-based therapeutics are gaining traction as a revolutionary approach in medicine, with glycoscience emerging as a pivotal field.
Guanabenz, an antihypertensive agent, has forensic applications in drug toxicity, criminal investigations, and veterinary medicine. The Guanabenz Forensic Kit aids in its detection.